Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal

Weigert, André; Querido, Sara; Carvalho, Lucas P.; Lebre, L.; Chagas, Cristina; Matias, Patrícia; Birne, Rita; Nascimento, C.; Jorge, Cristina; Adragão, Teresa; Bruges, Margarida; Machado, Domingos

doi:10.1016/j.transproceed.2018.02.017

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The efficacy and safety of DAA agents have been studied, with promising results in which sustained virologic response rates are compatible to the SVR rates of non‐transplant patients, allowing an entire population access to HCV treatment. A lot of reports of patients treated with SOF/LDV revealed significant results and safety for the kidney grafts . From our series, the use of SOF/LDV contributed to the excellent results and few adverse effects.…”

Section: Discussionsupporting

confidence: 56%

Safety of Direct‐Acting Antiviral Therapy for Renal Function in Post‐Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12‐Week Sustained Virologic Response: A Single‐Center Study

et al. 2019

View full text Add to dashboard Cite

Treatment of chronic hepatitis C infection after renal transplantation has been controversial due to the high rate of graft rejections with interferon (IFN)‐based therapies. The aim of this study is to review our experience of direct acting antiviral therapy for the recipients of renal transplantation. Eleven recipients who were hepatitis C virus‐polymerase chain reaction (PCR) positive were eligible for the treatment with direct acting antivirals. Six recipients were treated with sofosbuvir and ledipasvir, three were treated with elbasvir and grazoprevir, and one was treated with sofosbuvir and ribavirin for 12 weeks. One recipient was treated with glecaprevir and pibrentasvir for 8 weeks. All of the 11 recipients exhibited sustained virologic response at week 12 after the end of treatment. Adverse events were scarce including the two recipients who switched to tacrolimus from cyclosporine at the beginning of the treatment. The direct acting antiviral therapy including new agents appears to be safe and highly efficacious for the recipients after renal transplantation.

show abstract

Section: Discussionsupporting

confidence: 56%

Safety of Direct‐Acting Antiviral Therapy for Renal Function in Post‐Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12‐Week Sustained Virologic Response: A Single‐Center Study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…We found 29 studies pertaining to KTRs. 29 , 30 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 , 124 , 125 The studies evaluated the following: GLE/PIB (1 study, N = 20), GZR/EBR (2 studies, N = 21), PrO ± D (2 studies, N = 33), SOF (6 studies, N = 117), SOF/DCV (7 studies, N = 351), SOF/LDV (9 studies, N = 300), and SOF/VEL (1 study, N = 10). Three retrospective, unadjusted studies also compared a variety of DAA regimens ( N = 86), mostly SOF/LDV or SOF/DCV, to no DAA treatment ( N = 63).…”

Section: Ckd G4–g5ndmentioning

confidence: 99%

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

“…Currently, only few studies in the literature, most of which included relatively small numbers of patients, have focused on KT recipients with CHC treated with DAAs (Table 4) [7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26]. (Table 4) that DAAs are highly effective in KT recipients, offering SVR rates comparable to those achieved in the non-transplant setting and therefore representing major progress in the elimination of HCV infection in this setting.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study

Darema

Filiopoulos

Marinaki

et al. 2020

aog

View full text Add to dashboard Cite

Background The recent interferon-free direct-acting antiviral (DAA) regimens have very good safety and efficacy profiles and are highly recommended for kidney transplant (KT) recipients with chronic hepatitis C (CHC). Methods All KT recipients with CHC followed at our hospital and who received therapy with the current DAAs were included. At the baseline visit, demographic, clinical and laboratory variables before and after KT, as well as at the commencement of DAAs, at the end of antiviral therapy and the end of follow up, were recorded, including assessment of glomerular filtration rate (eGFR). The changes in eGFR (DGFR) between baseline and end of therapy (1 st period), and between end of therapy and end of follow up (2 nd period), were evaluated. Results Twelve KT recipients were retrospectively evaluated: 2 had received antiviral therapy in the past; 4 (33.3%) patients had genotype 1 and 3 (25%) genotype 4 CHC. The median stiffness was 11.9 kPa (range 5-16.8), while 5 patients, none with decompensated cirrhosis, had stiffness >12.5 kPa. Eight patients received a sofosbuvir-containing antiviral regimen (Group 1) and 4 patients received an antiviral regimen without sofosbuvir (Group 2). Eleven (91.7%) patients achieved a sustained virological response (SVR). One patient discontinued DAAs early after treatment and did not achieve SVR. Otherwise, DAAs were well tolerated and no rejection episode was recorded. The DGFRs in the 1 st period and 2 nd period did not differ significantly between Group 1 and Group 2 patients. Conclusion In this real-world study of KT recipients with CHC, the high efficacy and clinically acceptable tolerability of DAAs were confirmed.

show abstract

Hepatitis C Virus Eradication in Kidney Transplant Recipients: A Single-Center Experience in Portugal

Cited by 8 publications

References 8 publications

Safety of Direct‐Acting Antiviral Therapy for Renal Function in Post‐Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12‐Week Sustained Virologic Response: A Single‐Center Study

Safety of Direct‐Acting Antiviral Therapy for Renal Function in Post‐Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12‐Week Sustained Virologic Response: A Single‐Center Study

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Efficacy and safety of new direct-acting antivirals in kidney transplant recipients with chronic hepatitis C: a single-center study

Contact Info

Product

Resources

About